Back to results
US 9,751,824 B2Granted
Acetyl salicyclic acid dimers, synthesis thereof, and uses thereof to prevent and treat complement-mediated disorders
AssigneeAurin Biotech Inc.
InventorsPatrick L. McGeer, Moonhee Lee, Edith G. McGeer
Life of this patent
Estimating the term…
Abstract
Dimers of acetyl salicylic acid, including 4,4′-diacetoxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid (DAS-1) and 5,5′-methylenebis(2-acetoxybenzoic acid) (DAS-2) are provided. Methods of blocking the C3 convertase stage of the alternative complement pathway, preventing formation of the membrane attack complex of complement, and preventing or treating a complement-mediated disorder in a mammal including the step of administering dimers of acetyl salicylic acid are also provided.
Claims4
A compound selected from the group consisting of
- 5,5′-methylenebis(2-acetoxybenzoic acid),
- 2-acetoxy-3-(4-acetoxy-3-carboxybenzyl)benzoic acid,
- 2-acetoxy-3-(3-acetoxy-4-carboxybenzyl)benzoic acid,
- 2-acetoxy-4-(4-acetoxy-3-carboxybenzyl)benzoic acid,
- 3,3′-methylenebis(2-acetoxybenzoic acid),
- 4,4′-methylenebis(2-acetoxybenzoic acid),
- and salts thereof.
4 more elements
A pharmaceutical composition comprising:
- a. a compound selected from the group consisting of:
- i. 5,5′-methylenebis(2-acetoxybenzoic acid),
- ii. 2-acetoxy-3-(4-acetoxy-3-carboxybenzyl)benzoic acid,
- iii. 2-acetoxy-3-(3-acetoxy-4-carboxybenzyl)benzoic acid,
- iv. 2-acetoxy-4-(4-acetoxy-3-carboxybenzyl)benzoic acid,
- v. 3,3′-methylenebis(2-acetoxybenzoic acid), and
- vi. 4,4′-methylenebis(2-acetoxybenzoic acid);
- and
- b. a pharmaceutically acceptable carrier.
6 more elements
Dependencies are inferred from the claim text.